Tourette Syndrome Treatment: Teva Acquires Emalex, Developer of a New Drug for Tics in Children and Adults
Teva Pharmaceutical Industries, an Israeli pharmaceutical corporation, has officially announced the acquisition of the biotech company Emalex Biosciences. This deal is aimed at expanding Teva’s presence in the innovative neurological disorder treatment segment, specifically through Emalex’s promising development for the therapy of Tourette syndrome in children and adolescents.
The financial terms of the agreement involve a total payout of up to $900 million. The majority of the funds, approximately $700 million, will be paid upfront immediately upon the closing of the deal. The remaining $200 million is reserved as milestone payments, contingent upon achieving specific commercial results and the drug’s market success.
The central asset of the acquisition is a new medicinal drug currently undergoing clinical trials. It targets a young patient group suffering from Tourette syndrome and is designed to provide more effective control over tics while reducing the risk of side effects. For Teva, this step is a vital part of its strategy to strengthen its portfolio of original medicines and bolster its position in the field of pediatric psychoneurology.
The integration of Emalex’s developments is expected to allow Teva to offer the market a modern solution for treating this rare condition, as the company continues to transform its business model by focusing on high-tech biopharmaceutical products. The deal will be finalized following standard regulatory approval procedures.
